Gapping up
In reaction to earnings/guidance:
- JEF +2.8% (also increases quarterly dividend by 33%; increases stock buyback authorization to $250 mln), .
Other news:
- BPFH +26.3% (SIVB to acquire BPFH)
- GRTS +19.7% (EcoR1 Capital discloses 9.99% stake)
- CERC +17% (announced results from its exploratory Phase 2 trial of the human anti-LIGHT (TNFSF14) monoclonal antibody CERC-002)
- CHU +13.6% (NYSE Regulation no longer intends to move forward with the delisting action)
- CHL +10.4% (NYSE Regulation no longer intends to move forward with the delisting action)
- CHA +9.1% (NYSE Regulation no longer intends to move forward with the delisting action)
- BTAI +8.1% (announced that BXCL501 met the primary and secondary endpoints of the TRANQUILITY trial at the 60 mcg dose level)
- ARAY +5.9% (Receives 510(k) FDA clearance for ClearRT Helical kVCT imaging for the Radixact treatment delivery system)
- JAMF +4.9% (ends 2020 running on more than 20 mln Apple devices globally)
- AIH +4.7% (terminates deal to acquire a 51% equity interest in Guangdong Hanfei)
- MYOV +4.7% (announces that ORGOVYX is now available through authorized specialty distributors)
- OESX +4.7% (entered into a new and expanded five-year $25.0 mln revolving credit facility effective December 29, 2020)
- DRNA +4.3% (announced Novo Nordisk (NVO) has nominated its first candidate under the existing agreement between the two companies for the discovery and development of novel therapies for the treatment of liver-related cardiometabolic diseases using Dicerna's proprietary GalXC RNAi platform technology)
- IDEX +3.4% (to acquire 100% of privately held Wireless Advanced Vehicle Electrification for cash and stock consideration)
- CO +2.4% (announces NHC policy update)
- MRNA +1% (receives authorization of its COVID-19 vaccine in Israel)
- MTZ +1% (MasTec's Precision Pipeline has been awarded a contract from TC Energy (TRP) for the construction of the Keystone XL Pipeline in Montana and South Dakota) .
Analyst comments:
- BBCP +5.2% (upgraded to Outperform from Neutral at Robert W. Baird)
- MU +3.2% (upgraded to Buy from Sell at Citigroup)
- JD +2.3% (upgraded to Buy from Sell at Citigroup)
- RJF +2.1% (upgraded to Buy from Sell at Goldman)
- CE +1.9% (upgraded to Outperform from Market Perform at BMO Capital Markets)
- PLAN +1.7% (upgraded to Overweight from Equal Weight at Wells Fargo)
- DIN +1.7% (upgraded to Buy from Hold at Deutsche Bank)
- ENPH +1.7% (upgraded to Buy from Neutral at Goldman)
- HUBS +1.7% (upgraded to Overweight from Equal Weight at Wells Fargo)
- THC +1.5% (upgraded to Buy from Neutral at BofA Securities)
- DOCU +1.4% (upgraded to Overweight from Neutral at Piper Sandler)
- IQ +1.4% (upgraded to Buy from Neutral at New Street)
- ALB +1.2% (upgraded to In-line from Underperform at Evercore ISI)